NBSE
NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE
Delisted
NBSE was delisted on the 10th of May, 2024.
40 hedge funds and large institutions have $10.7M invested in NeuBase Therapeutics, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
4% less call options, than puts
Call options by funds: $140K | Put options by funds: $146K
Holders
40
Holding in Top 10
–
Calls
$140K
Puts
$146K
Top Buyers
| 1 | +$936K | |
| 2 | +$487K | |
| 3 | +$429K | |
| 4 |
CC
Cannell & Co
New York
|
+$370K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$156K |
Top Sellers
| 1 | -$110K | |
| 2 | -$45.5K | |
| 3 | -$31.3K | |
| 4 |
VF
Virtu Financial
New York
|
-$24K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$23.8K |